Vector-borne diseases (VBDs) pose a significant public health challenge in India, with a high burden of morbidity and mortality. This article provides a comprehensive overview of the prevalence and management of VBDs in the country, offering valuable insights for healthcare professionals.
India is endemic to several VBDs, including malaria, dengue, chikungunya, and Japanese encephalitis. The National Vector Borne Disease Control Programme (NVBDCP) reports that malaria alone accounts for 1.5 million cases annually. Dengue cases have also seen a sharp increase in recent years, with over 100,000 cases reported in 2017.
The management of VBDs in India is fraught with challenges. These include inadequate surveillance, lack of public awareness, and socio-economic factors. The vast geographical diversity of India also plays a role in the spread and control of these diseases.
The NVBDCP implements various strategies for controlling VBDs, including vector control, early case detection, and prompt treatment. The government has also launched the National Health Mission (NHM) to strengthen healthcare delivery at the grassroots level. Despite these efforts, the burden of VBDs remains high, necessitating more effective strategies.
Healthcare professionals play a critical role in managing VBDs. They are responsible for early diagnosis, appropriate treatment, and patient education. Their role also extends to community engagement, where they can contribute to disease prevention by raising awareness about vector control and personal protection.
Despite significant challenges, there is a growing recognition of the importance of managing VBDs in India. The role of healthcare professionals is pivotal in this endeavor. By fostering a better understanding of the prevalence and management of these diseases, this guide aims to equip healthcare professionals with the knowledge required to combat VBDs effectively.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation